Form 4: Agios Pharmaceuticals Director Rahul Ballal Reports Stock Transactions

Director Rahul Ballal reports transactions involving Agios Pharmaceuticals common stock and restricted stock units.

Summary

• On August 11, 2024, Rahul Ballal, a director of Agios Pharmaceuticals, engaged in transactions involving the company's stock.
• Ballal acquired 2,302 shares of common stock through the vesting of restricted stock units.
• Concurrently, Ballal disposed of 7,992 shares of common stock.
• Following these transactions, Ballal directly owns 2,302 derivative securities and 7,992 shares of common stock.
• The restricted stock units were granted on August 11, 2022, and vest in three equal annual installments beginning August 11, 2023.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock. It is common for directors and officers to receive stock options or restricted stock units as part of their compensation, and their subsequent exercise or sale of these securities is closely monitored by investors.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company insiders as it can provide insights into their confidence in the company's future prospects.

Key Dates